ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
01/12/2025
Voltar para busca
Dado oficial do USPTO
GQ
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
33
Atualização mais recente
02/12/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 40, 42
Data de depósito
11/10/2022
Data de registro
06/08/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
06/08/2024
Última transação
02/12/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Código do desenho
4
Tipo de titular
27
Localização do titular
HAMBURG, DE
Examinador
BACZESKI,LILLIANNA M
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
PACIRA GERMANY GMBH
GQ BIO THERAPEUTICS GMBH
GeneQuine Biotherapeutics GmbH
Representantes
Keith Toms, Esq. McCarter & English, LLP
Classificação técnica
Classes Nice
Classe 5Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Vaccines; Analgesic preparations; Anti-arthritic compositions and preparations; Anti-cancer preparations; Anti-inflammatory preparations; Biological preparations for the treatment of cancer; Biological preparations for the treatment of musculoskeletalgeneticmetabolicendocrinecardiovascularcardiopulmonarygenitourinaryoncologicalhepatologicalnephrologicalhematologicalophthalmicrespiratoryneurologicalgastrointestinalhormonalinfectiousdermatologicalimmune system related diseases and disorders; Biological tissue cultures for medical purposes; Biological tissue cultures for veterinary purposes; Biological skin tissuesliver tissuesjoint tissuesbonecartilagesynoviumtendon tissuesall intended for subsequent implantation; Cells for medical or clinical use; Diagnostic agentspreparations and substances for medical purposes; Diagnostic preparations for medical or veterinary purposes; Drug testing kits comprised of medical diagnostic reagents and assays for testing body fluids; Gene therapy productsgenetically engineered tissues for transplant purposes; Human vaccine preparations; Medicaments for promoting recovery from tendon and muscle injuries and disorders and sports related injuries; Nucleic acid sequences and chemical reagents for medical and veterinary purposes; Pain relief medication; Pharmaceutical preparation for the treatment of gout; Pharmaceutical preparations for the treatment and prevention of musculoskeletalgeneticmetabolicendocrinecardiovascularcerebrovascularcardiopulmonarygenitourinaryoncologicalhepatologicalnephrologicalhematologicalophthalmicrespiratoryneurologicalgastrointestinalhormonalinfectiousdermatologicalimmune system related diseases and disorders; Veterinary pharmaceutical preparations for the prevention of musculoskeletalgeneticmetabolicendocrinecardiovascularpulmonarygenitourinaryoncologicalhepatologicalhematologicalophthalmicrespiratoryneurologicalgastrointestinalhormonalinfectiousdermatologicalimmune system related diseases and disorders; Veterinary pharmaceutical preparations for the treatment of musculoskeletalgeneticmetabolicendocrinecardiovascularpulmonarygenitourinaryoncologicalhepatologicalhematologicalophthalmicrespiratoryneurologicalgastrointestinalhormonalinfectiousdermatologicalimmune system related diseases and disorders; Veterinary preparationspain relief medication; Veterinary vaccines; In vitro diagnostic preparations for medical use
Classe 40
Biomanufacturing for othersmanufacturing of biologicsvaccinesnon-viral and viral vectorsgene and cell therapy preparationsall using biological organisms in the manufacturing process; Custom manufacture of pharmaceuticalsbiologicsvaccinesbiotechnological productsnon-viral and viral vectorsgene and cell therapy preparations by pharmaceutical compounders; Custom manufacture of pharmaceuticalsbiologicsvaccinesbiotechnological medicationsnon-viral and viral vectorsgene and cell therapy preparations; Manufacturing process consulting; Manufacturing services for others in the field of pharmaceuticalsbiologicsvaccinesnon-viral and viral vectorsgene therapy and gene and cell therapy preparations; Technical support servicesproviding technical advice related to the manufacture of biologicsgene therapy preparationsvaccinesnon-viral and viral vectors
Classe 42
Consulting services in the field of pharmaceutical research and development; Providing reagent sample testing and diagnostic services for others for scientific research purposes; Research and development in the field of geneticsgene therapycell therapyvaccinesbiotechnological productionnon-viral and viral vector production; Pharmaceutical drug development services for prevention and treatment of musculoskeletalgeneticophthalmicmetabolicendocrinecardiovascularcerebrovascularcardiopulmonarygenitourinaryoncologicalhepatologicalnephrologicalhematologicalrespiratoryneurologicalgastrointestinalhormonalinfectiousdermatologicalimmune system related diseases and disorders; Research and development in the pharmaceutical and biotechnology fields; Research and development of vaccines and medicines; Scientific research and development; Scientific research consulting in the field of geneticsgene therapycell therapyvaccinesbiotechnological productionnon-viral and viral vector production; Scientific research for medical purposes in the field of musculoskeletalgeneticmetabolicendocrinecardiovascularcerebrovascularcardiopulmonarygenitourinaryoncologicalhepatologicalnephrologicalhematologicalophthalmicrespiratoryneurologicalgastrointestinalhormonalinfectiousdermatologicalimmune system related diseases and disorders; Scientific research in the field of genetics and genetic engineering; Testinginspectionresearchdevelopment of pharmaceutical preparations for gene therapy
Publicações
Histórico de despachos e eventos da marca no USPTO.
33 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
01/10/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
01/10/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
01/10/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
20/08/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
20/08/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
20/08/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
20/08/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
20/08/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
20/08/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
06/08/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
06/08/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/05/2024
PUBO
PUBLISHED FOR OPPOSITION
21/05/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/05/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
15/04/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/04/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/04/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
11/04/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
21/02/2024
GNRT
NON-FINAL ACTION E-MAILED
21/02/2024
CNRT
NON-FINAL ACTION WRITTEN
21/02/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
22/01/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
22/01/2024
ALIE
ASSIGNED TO LIE
22/01/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
31/08/2023
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
23/08/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
14/08/2023
GNRT
NON-FINAL ACTION E-MAILED
14/08/2023
CNRT
NON-FINAL ACTION WRITTEN
14/08/2023
DOCK
ASSIGNED TO EXAMINER
26/07/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
26/10/2022
NWAP
NEW APPLICATION ENTERED
14/10/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace GQ ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.